Is DNA testing for hypertrophic cardiomyopathy cost-effective?

Is DNA testing for hypertrophic cardiomyopathy cost-effective?

Bibliographic Details
Main Authors:	Wordsworth, S, Leal, J, Legood, R, Taylor, J, Thomson, K, Seller, A, Watkins, H, Blair, E
Format:	Conference item
Published:	2006

Similar Items

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model
by: Wordsworth, S, et al.
Published: (2010)

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.
by: Wordsworth, S, et al.
Published: (2010)

Linked genetic modifiers in hypertrophic cardiomyopathy
by: Ektisham, J, et al.
Published: (2004)

Ascertainment strategies and genotype:phenotype correlations in hypertrophic cardiomyopathy.
by: Blair, E, et al.
Published: (2003)

Sudden death in hypertrophic cardiomyopathy.
by: Watkins, H
Published: (2000)

Expansion of a diagnostic service for hypertrophic cardiomyopathy using next generation sequencing
by: Reid, S, et al.
Published: (2011)

Myocardial dysfunction in hypertrophic cardiomyopathy.
by: Ashrafian, H, et al.
Published: (2001)

Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.
by: Ashrafian, H, et al.
Published: (2003)

A fast-throughput service for Familial Hypertrophic and Dilated Cardiomyopathy using High resolution melt curve analysis on the Lightscanner
by: Thistleton, J, et al.
Published: (2007)

Early onset malignant hypertrophic cardiomyopathy caused by mutations in MYBPC3
by: Carballo, S, et al.
Published: (2003)

Evaluation of Clinical Diagnostic Potential of Next Generation Sequencing using Hypertrophic Cardiomyopathy as a Model
by: Taylor, J, et al.
Published: (2010)

Metabolic perturbations in the pathogenesis of hypertrophic cardiomyopathy
by: Ashrafian, H, et al.
Published: (2005)

Hypertrophic cardiomyopathy in Noonan Syndrome closely mimics familial hypertrophic cardiomyopathy due to sarcomeric mutations.
by: Hudsmith, L, et al.
Published: (2006)

Novel mutations in cardiac MYBPC3 and early onset malignant hypertrophic cardiomyopathy
by: Carballo, S, et al.
Published: (2005)

Oxford Molecular Genetics Laboratory Cardiomyopathy Service
by: Thistleton, J, et al.
Published: (2006)

The genetics of hypertrophic cardiomyopathy: Teare redux.
by: Watkins, H, et al.
Published: (2008)

Identification of a novel mitochondrial DNA mutation in the ND1 gene in 2 patients with hypertrophic cardiomyopathy with restrictive physiology
by: Khogali, S, et al.
Published: (2001)

Novel mutations in cardiac MYBPC3 causing early onset malignant hypertrophic cardiomyopathy
by: Carballo, S, et al.
Published: (2005)

Double mutations in CIS can confound genotype-phenotype correlations in hypertrophic cardiomyopathy
by: Blair, E, et al.
Published: (2000)

Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy.
by: Blair, E, et al.
Published: (2001)

Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies.
by: Watkins, H
Published: (2003)

Novel mutations in cardiac MYPBC3 cause early onset malignant hypertrophic cardiomyopathy (HCM)
by: Carballo, S, et al.
Published: (2005)

Cardiac Steatosis Detected in Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy and Aortic Stenosis
by: Suttie, J, et al.
Published: (2011)

Correlates of myocardial fibrosis in hypertrophic cardiomyopathy
by: Kramer, CM, et al.
Published: (2018)

The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy.
by: Watkins, H, et al.
Published: (2005)

Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management
by: Watkins, H
Published: (2001)

Assigning a causal role to genetic variants in hypertrophic cardiomyopathy.
by: Watkins, H
Published: (2013)

Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy.
by: Ashrafian, H, et al.
Published: (2011)

Data-driven modelling of mutational hotspots and in silico predictors in hypertrophic cardiomyopathy
by: Waring, A, et al.
Published: (2020)

A novel mutation in phospholamban causes a mixed hypertrophic and dilated cardiomyopathy phenotype with autosomal dominant inheritance
by: Carballo, S, et al.
Published: (2004)

The genetic architecture of hypertrophic cardiomyopathy
by: Harper, AR
Published: (2020)

Functional analysis of hypertrophic cardiomyopathy missense mutations in the light meromyosin region of beta myosin heavy chain
by: Redwood, C, et al.
Published: (2003)

Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry
by: Neubauer, S, et al.
Published: (2019)

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy
by: Coleman, JA, et al.
Published: (2024)

Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin
by: Toepfer, C, et al.
Published: (2019)

Identification of a novel mitochondrial NADH dehydrogenase I (MTND1) gene mutation in two patients with hypertrophic cardiomyopathy
by: Khogali, S, et al.
Published: (2001)

Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy.
by: Edwards, R, et al.
Published: (1970)

EFFECTS OF PROPRANOLOL ON RESPONSE TO EXERCISE IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
by: Edwards, R, et al.
Published: (1970)

Investigation of troponin I mutations causing familial hypertrophic cardiomyopathy
by: Abdulrazzak, H, et al.
Published: (2001)

METABOLIC ALTERATION IN HYPERTROPHIC CARDIOMYOPATHY (METAL-HCM STUDY): RANDOMISED DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF PERHEXILINE THERAPY IN PATIENT WITH HYPERTROPHIC CARDIOMYOPATHY
by: Abozguia, K, et al.
Published: (2010)